Trial Profile

A global Phase 3 clinical program of KAI-9531.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Nov 2025 New trial record
04 Nov 2025 Kailera's global Phase 3 program is evaluating multiple maintenance doses, including 8 mg and 10 mg, and at least 52 weeks of maintenance dosing. company plans to initiate this program by year end 2025.
14 Oct 2025 According to Kailera Therapeutics media release, company announced a $600 million Series B financing led by new investor Bain Capital Private Equity. The financing will be fully funded at closing and will support the advancement of Kaileras leading obesity portfolio, including a global Phase 3 clinical program.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com